Arrowhead Pharm saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an upgrade from 77 to 89.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's unique rating measures share price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.
History shows that the stocks that go on to make the biggest gains typically have an 80 or higher RS Rating as they begin their biggest runs.
While Arrowhead Pharm is not near an ideal buy zone right now, see if it goes on to form and break out of a proper base.
Arrowhead Pharm posted 0% EPS growth in the latest quarterly report. Sales rose -30%.
The company earns the No. 52 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
